Our results demonstrate the consequence of loss of DAB2IP in ER+ breast cancer, specifically focused on Luminal A breast cancer, and provide insight into underlying mechanisms that lead to the aggressiveness of this subset of tumors. The gene discussed is DAB2IP; the disease is breast cancer.